[NMusers] Simulo (clinical trail simulator) Workshop at PAGE 2018

2018-04-24 Thread Faelens, Ruben (Belgium)
Dear all, PAGE is getting closer and the available seats in the Simulo (Exprimo's unique clinical trail simulator) workshop getting fewer. Please save you seat now! Check out the details here: https://exprimo.com/article/two-day-clinical-trial-simulation-course-page-2018 SGS Exprimo is running a

Re: [NMusers] ETAs & SIGMA in external validation

2018-04-13 Thread Faelens, Ruben (Belgium)
yway. Good luck with your project! Please excuse my brevity, this was sent from a mobile device From: Tingjie Guo Sent: Friday, April 13, 2018 5:20:40 PM To: Jakob Ribbing Cc: Faelens, Ruben (Belgium); nmusers@globomaxnm.com Subject: Re: [NMusers] ETAs & SIGM

RE: [NMusers] ETAs & SIGMA in external validation

2018-04-09 Thread Faelens, Ruben (Belgium)
Hi Tingjie, A lot of great tips and explanations already. Just wanted to add my two cents. POSTHOC will estimate the most likely ETA for each individual, taking into account the known population parameters THETA and OMEGA. “Most likely” means: 1. An individual parameter as close as possible

[NMusers] RE: R for regulatory use

2018-03-23 Thread Faelens, Ruben (Belgium)
Dear Christina, I would love to learn a bit more about this, and an open discussion on this list is probably the best way. Could you elaborate how specifically the open source nature of R causes concern? See the nice documentation from the R project core team at https://www.r-project.org/doc/R-

[NMusers] Two-day clinical trial simulation course at PAGE 2018

2018-01-18 Thread Faelens, Ruben (Belgium)
Dear colleagues, In the context of the next PAGE meeting, SGS Exprimo is running a two-day Clinical Trial Simulation course on Monday and Tuesday 28-29 May. * The course on Monday will introduce attendees to Simulo, a PK-PD-Disease model simulator developed for 6 years and now available

[NMusers] RE: question about random seed for simulation

2017-03-09 Thread Faelens, Ruben (Belgium)
Hi Penny, Nonmem indeed calculates each subject one after the other. The random values will therefore change. Maybe you can set the random seed every time you simulate t=0, based on the subject ID? This may also depend on your data file; have you tried ordering on time (so the first 50 rows are

RE: [NMusers] Usage of parallel nonmem in tendem with SGE

2016-04-29 Thread Faelens, Ruben (Belgium)
Hi Paul, How are you launching jobs? Are you launching nmfe using qsub -pe myqueue 4 ./nmfe-launch.sh ? I may be mistaken, but I assume that SGE should automatically handle this sort of thing, no? If you specified the correct number of slots in the cluster queue, only that amount of cores shoul

[NMusers] MS-MPI with Nonmem: experiences?

2016-03-16 Thread Faelens, Ruben (Belgium)
Dear group, The MPI library of choice for Nonmem has been MPICH2 for quite some time now. Since the last release of MPICH2 on April 2013, the package has been unsupported on Windows. The developers of MPICH2 actually recommend migrating to MS-MPI. By adding the required libraries to the compile

RE: [NMusers] Gfortran problems in yosemite

2016-02-23 Thread Faelens, Ruben (Belgium)
Dear Adedeji, This is probably the cause of the problem: Fatal Error: Cannot read module file 'fsizes.mod' opened at (1), because it was created by a different version of GNU Fortran Every time you install NONMEM, it will recompile the standard functions modules using your current compiler. The

RE: [NMusers] setup of parallel processing and supporting software - help wanted

2015-12-09 Thread Faelens, Ruben (Belgium)
Hi Pavel, In general, parallelization discussions always revolve around the following question: “Can you create independent blocks of work?” You should make a clear distinction here between parallelizing nonmem, and running several nonmem runs in parallel. Let’s talk about estimating of a singl

[NMusers] Simulo: a new service for drug trial simulation

2015-06-23 Thread Faelens, Ruben (Belgium)
Dear NONMEM users, We all know how difficult it is to simulate full drug trials using NONMEM. It is often necessary to generate the full dosing scheme(s) beforehand, and response-based dose adaptation requires iteratively rerunning your model until you have the results you are happy with. At S